Seeking Alpha

Seeking Alpha Portfolio App for iPad

4,761 people get MDT articles and Market Currents by email alert.

Get email alerts on MDT »

MDT

Medtronic Inc.

5/22/2013, 2:55 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 21, 8:39 AM More on Medtronic's (MDT) FQ4: Revenues grow 5% Y/Y on a constant currency basis while non-GAAP EPS growth comes in at 11%. International revenue grows 7% Y/Y and accounts for 47% of total worldwide sales. CEO Omar Ishrak says the results underscore the company's commitment to "delivering consistent and dependable growth." By segment, the Cardiac and Vascular group saw revenues grow 5%, while sales rose 4% in the Resorative Therapies unit. MDT says it sees FY14 revenue grow of 3-4% and EPS of $3.80-$3.82 against consensus of 3.84. Shares +4.25% premarket. (PR) Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 21, 7:20 AM Medtronic (MDT): Q1 EPS of $1.10 beats by $0.07. Revenue of $4.5B beats by $0.11B. Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 21, 12:05 AM Notable earnings before Tuesday’s open: AZO, BBY, DCIX, DKS,HD, MDT, NM, SKS, TJX Comment! [Earnings]
Monday, May 20, 5:30 PM Notable earnings before Tuesday’s open: AZO, BBY, DCIX, DKS,HD, MDT, NM, SKS, TJX Comment! [Earnings]
Friday, May 10, 4:33 PM Medtronic (MDT) says data presented at the Heart Rhythm Society's 34th Annual Scientific Sessions show its Lead Integrity Alert software detected pace/sense lead issues in non-MDT leads at a greater rate than standard impedance monitoring alone. The analysis, which focused on BSX's Endotak leads, shows that for every one Endotak pace/sense lead issue detected by impedance monitoring, the LIA software detected four cases that were missed. Comment! [Healthcare]
Monday, April 29, 3:59 PM Vascular specialists at Carolinas HealthCare System in Charlotte, North Carolina, and the Cleveland Clinic in Ohio perform the initial implants of a novel stent graft system from Medtronic (MDT +1%) as part of an FDA initiative designed to encourage more early-stage clinical research on new medical devices in the U.S. The implants are among the first to be performed under the agency's early feasibility pilot program, which includes a total of nine medical devices from different companies. Comment! [Healthcare]
Monday, April 22, 8:43 AM Arca Biopharma (ABIO) soars 35% premarket. The company says it will collaborate with Medtronic (MDT) on a Phase 2b clinical trial for Gencaro, ABIO's lead developmental drug for the treatment of cardiac rhythm disorders. Comment! [Healthcare, On the Move]
Thursday, April 11, 1:48 PM Medtronic (MDT +1.3%) moves up today after saying it's initiated enrollment of the first patient in its SubQStim II clinical trial which uses peripheral nerve stimulation, also known as subcutaneous nerve stimulation, to reduce chronic, intractable post-surgical back pain. Comment! [Healthcare, On the Move]
Tuesday, April 9, 3:03 PM Medtronic (MDT +1.1%) gains after saying it's released its CardioGuide Implant System, a real-time navigation system for pacemakers and defibrillators in the U.S. and Canada. The system helps physicians determine the most appropriate location for left-ventricular lead placement by generating 3-D images of the cardiac veins. Enhanced software for the system will be commercially available later this year that also analyzes the motion of select cardiac vessels on the left side of the heart. Comment! [Healthcare]
Monday, February 25, 1:51 PM Medtronic (MDT -0.3%) says the FDA has approved the 34mm and 38mm lengths of its Resolute Integrity drug-eluting stent for treating patients with diabetes. The new sizes will enable the treatment of long coronary lesions, which are generally considered to span more than 27mm, and are uniquely indicated for treating coronary artery disease in patients with diabetes, who commonly present with long lesions. Comment! [Healthcare]
Tuesday, February 19, 8:09 AM More on Medtronic (MDT) FQ3: net profit +5.7% to $988M; Sales breakdown: cardiac rhythm disease management -1% excluding currency fluctuations; spinal products -3%. Affirms 2013 guidance for EPS of $3.66-3.70 vs forecasts of $3.68 and revenue growth of 3-4% at constant currencies. Comment! [Healthcare, Earnings]
Tuesday, February 19, 7:30 AM Medtronic (MDT): FQ3 EPS of $0.93 beats by $0.02. Revenue of $4.03B (+3% Y/Y) in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 19, 12:05 AM Notable earnings before Tuesday’s open: ACT, BCRX, DCIX, FUN, GPC, MDT, MRGE, NGPC, NI, NM, ROC, SAVE, SEE, WAB, WIN, XEC, YNDX Comment! [Earnings]
Monday, February 18, 5:30 PM Notable earnings before Tuesday’s open: ACT, BCRX, DCIX, FUN, GPC, MDT, MRGE, NGPC, NI, NM, ROC, SAVE, SEE, WAB, WIN, XEC, YNDX Comment! [Earnings]
Wednesday, February 13, 3:26 PM Medtronic (MDT -0.2%) says its received FDA clearance for its AIRvance Bone Screw System, allowing surgeons to perform a hyoid suspension procedure independently or in combination with other procedures for the treatment of obstructive sleep apnea. Under its previous FDA clearance, the hyoid suspension procedure was indicated as an adjunct to the tongue suspension procedure. With this clearance, the AIRvance System becomes the only approved stand-alone system available. Comment! [Healthcare]
Wednesday, February 13, 9:55 AM The FDA approves Medtronic's (MDT +0.1%) Advisa DR MRI SureScan pacing system, the company's next-generation pacemaker that enables patients to receive MRI scans, something that is not allowed with traditional pacemakers. It's worth noting that up to 75% of patients with implanted heart devices worldwide are expected to need an MRI scan during the lifetime of those devices. (PR) Comment! [Healthcare]

1
2
3
4
5
6
...
11
Next Page